Jefferson City Headlines

DelveInsight’s “Gastric Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastric Cancer, historical and forecasted epidemiology as well as the Gastric Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastric Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastric Cancer Market Forecast

Some of the key facts of the Gastric Cancer Market Report: 

• The Gastric Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In May 2023, CARsgen Therapeutics, a Chinese biotech firm, initiated a Phase II clinical study of CT041 in the United States. This trial is enrolling participants with advanced gastric cancer or gastroesophageal junction cancer who test positive for Claudin18.2 (CLDN18.2). CT041 is a candidate autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CLDN18.2 protein.
• The American Cancer Society’s projections for gastric cancer in the United States in 2022 indicate approximately 26,380 new cases, comprising 15,900 in men and 10,480 in women. Additionally, it estimates around 11,090 deaths attributed to this form of cancer, with 6,690 among men and 4,400 among women.
• Among the 7MM, Japan (135,592 cases in 2021) has the highest and UK (6,682 cases in 2021) has the lowest number of incident cases of Gastric Cancer
• In the EU4 and the UK nations, Italy has the highest incidence rate at 24.7 per 100,000, trailed by Spain (23.1), Germany (21.6), France (17.0), and the UK (14.2).
• Key Gastric Cancer Companies: Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others
• Key Gastric Cancer Therapies: FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others
• The Gastric Cancer epidemiology based on gender analyzed that gastric cancer is 2.2 times more likely to be diagnosed in males than females
• The Gastric Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastric Cancer pipeline products will significantly revolutionize the Gastric Cancer market dynamics.

Gastric Cancer Overview

Gastric cancer, also known as stomach cancer, refers to the development of malignant tumors in the lining of the stomach. It typically begins in the innermost layer of the stomach wall and can gradually spread to other layers and nearby organs if not diagnosed and treated early. Gastric cancer is often asymptomatic in its early stages, making it challenging to detect, but as it progresses, symptoms may include indigestion, abdominal discomfort or pain, nausea, vomiting, unintentional weight loss, and blood in the stool.

Get a Free sample for the Gastric Cancer Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/gastric-cancer-market

Gastric Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastric Cancer Epidemiology Segmentation:

The Gastric Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Gastric Cancer
• Prevalent Cases of Gastric Cancer by severity
• Gender-specific Prevalence of Gastric Cancer
• Diagnosed Cases of Episodic and Chronic Gastric Cancer

Download the report to understand which factors are driving Gastric Cancer epidemiology trends @ Gastric Cancer Epidemiology Forecast

Gastric Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastric Cancer market or expected to get launched during the study period. The analysis covers Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastric Cancer Therapies and Key Companies

• FMPV-1: Hubro Therapeutics
• CE008: Cello Therapeutics
• Venadaparib: Idience
• DKN-01: Leap Therapeutics
• Abemaciclib: Eli Lilly and Company
• Tislelizumab : BeiGene
• Fruquintinib: Hutchison MediPharma
• Zolbetuximab: Astellas Pharma
• HLX10: Henlix Biotech
• Camrelizumab: Jiangsu Hengrui Medicine
• Catumaxomab: Neovii Biotech
• Amivantamab: Genmab/Janssen Biotech
• RAPA-201: Rapa Therapeutics LLC
• HC 5404 FU: HiberCell, Inc.

Discover more about therapies set to grab major Gastric Cancer market share @ Gastric Cancer Treatment Landscape

Gastric Cancer Market Strengths

• In-depth understanding of molecular heterogeneity of tumor and pathogenesis
• Scientific advances and identification of novel therapeutic targets for treatment

Gastric Cancer Market Opportunities

• Future development of potential biomarkers may improve screening and early detection of gastric cancers, with better accuracy, in the future.
• Increase in the awareness of gastric cancers and encouraging regular screening.

Scope of the Gastric Cancer Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Gastric Cancer Companies: Hubro Therapeutics, Cello Therapeutics, Idience, Leap Therapeutics, Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix Biotech, Jiangsu Hengrui Medicine, Neovii Biotech, Genmab/Janssen Biotech, Rapa Therapeutics LLC, HiberCell, Inc., and others
• Key Gastric Cancer Therapies: FMPV-1, CE008, Venadaparib, DKN-01, Abemaciclib, Tislelizumab, Fruquintinib, Zolbetuximab, HLX10, Camrelizumab, Catumaxomab, Amivantamab, RAPA-201, HC 5404 FU, and others
• Gastric Cancer Therapeutic Assessment: Gastric Cancer current marketed and Gastric Cancer emerging therapies
• Gastric Cancer Market Dynamics: Gastric Cancer market drivers and Gastric Cancer market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastric Cancer Unmet Needs, KOL’s views, Analyst’s views, Gastric Cancer Market Access and Reimbursement 

To know more about Gastric Cancer companies working in the treatment market, visit @ Gastric Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Gastric Cancer Market Report Introduction

2. Executive Summary for Gastric Cancer

3. SWOT analysis of Gastric Cancer

4. Gastric Cancer Patient Share (%) Overview at a Glance

5. Gastric Cancer Market Overview at a Glance

6. Gastric Cancer Disease Background and Overview

7. Gastric Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastric Cancer 

9. Gastric Cancer Current Treatment and Medical Practices

10. Gastric Cancer Unmet Needs

11. Gastric Cancer Emerging Therapies

12. Gastric Cancer Market Outlook

13. Country-Wise Gastric Cancer Market Analysis (2019–2032)

14. Gastric Cancer Market Access and Reimbursement of Therapies

15. Gastric Cancer Market Drivers

16. Gastric Cancer Market Barriers

17.  Gastric Cancer Appendix

18. Gastric Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/